HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Receivables (2015 - 2026)

HUTCHMED (China)'s (HMDCF) quarterly Receivables came in at $161.6 million in Q2 2026, down 18.24% year-over-year from $197.6 million in Q2 2025, and down 9.5% quarter-over-quarter from $178.5 million in Q4 2025.

Analysis

HUTCHMED (China) (HMDCF) Receivables (2015 - 2026) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Receivables for 12 consecutive years, with $161.6 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Receivables fell 18.24% year-over-year to $161.6 million in Q2 2026; TTM through Jun 2026 was $161.6 million, a 18.24% decrease from a year earlier, with the FY2025 full-year figure at $178.5 million, changed N/A from the prior year.
  • Receivables was $161.6 million for Q2 2026 at HUTCHMED (China), down from $178.5 million in the prior quarter.
  • Over five years, Receivables peaked at $197.6 million in Q2 2025 and troughed at $8.3 million in Q4 2023.
  • A 5-year average of $121.6 million and a median of $156.4 million in 2023 frame the typical range for Receivables.
  • Across the five-year window, Receivables soared 395.16% in 2022 and plunged 31.37% in 2023, its largest moves.
  • Over 5 years, Receivables stood at $12.1 million in 2022, then slumped by 31.37% to $8.3 million in 2023, then surged by 2128.75% to $184.7 million in 2024, then declined by 3.31% to $178.5 million in 2025, then declined by 9.5% to $161.6 million in 2026.
  • The last three Receivables figures came in at $161.6 million (Q2 2026), $178.5 million (Q4 2025), and $197.6 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Amgen 210.98 Bn 196.99 Bn 7.24 Bn 10.23 Bn
2 Gilead Sciences 181.24 Bn 178.06 Bn 6.22 Bn 5.90 Bn
3 Vertex Pharmaceuticals 132.38 Bn 124.53 Bn 2.84 Bn 2.13 Bn
4 Regeneron Pharmaceuticals 82.97 Bn 74.97 Bn 3.93 Bn 6.57 Bn
5 Argenx Se 61.59 Bn 56.41 Bn 1.37 Bn 1.93 Bn
6 Moderna 54.80 Bn 49.67 Bn 52.00 Mn 160.00 Mn
7 Alnylam Pharmaceuticals 34.09 Bn 30.78 Bn 992.69 Mn 912.74 Mn
8 Biogen 31.34 Bn 30.05 Bn 1.96 Bn 1.89 Bn
9 Roivant Sciences 30.11 Bn 30.11 Bn 1.16 Mn -
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - 161.58 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 161.58 Mn
Dec 31, 2025 178.55 Mn
Jun 30, 2025 197.63 Mn
Jun 30, 2024 184.65 Mn
Dec 31, 2023 8.29 Mn
Jun 30, 2023 151.16 Mn
Dec 31, 2022 12.07 Mn
Jun 30, 2022 78.89 Mn
Dec 31, 2021 -4.09 Mn
Jun 30, 2021 82.20 Mn
Mar 31, 2021 53.13 Mn
Dec 31, 2020 -6.65 Mn
Jun 30, 2020 59.88 Mn
Dec 31, 2019 36.94 Mn
Sep 30, 2019 44.57 Mn
Jun 30, 2019 44.57 Mn
Mar 31, 2019 44.55 Mn
Dec 31, 2018 2.41 Mn
Jun 30, 2018 47.27 Mn
Dec 31, 2017 7.20 Mn